MX2021002215A - Derivados de tetrahidropiridopirimidina como moduladores de ahr. - Google Patents
Derivados de tetrahidropiridopirimidina como moduladores de ahr.Info
- Publication number
- MX2021002215A MX2021002215A MX2021002215A MX2021002215A MX2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A MX 2021002215 A MX2021002215 A MX 2021002215A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydropyrido
- pyrimidine derivatives
- compounds
- ahr modulators
- ahr
- Prior art date
Links
- FHLXQXCQSUICIN-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[3,2-d]pyrimidine Chemical class C1=CC=C2NCNCC2=N1 FHLXQXCQSUICIN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201807244X | 2018-08-24 | ||
| PCT/EP2019/072641 WO2020039093A1 (en) | 2018-08-24 | 2019-08-23 | Tetrahydropyridopyrimidine derivatives as ahr modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002215A true MX2021002215A (es) | 2021-07-15 |
Family
ID=67982013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002215A MX2021002215A (es) | 2018-08-24 | 2019-08-23 | Derivados de tetrahidropiridopirimidina como moduladores de ahr. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12221439B2 (https=) |
| EP (1) | EP3841102B1 (https=) |
| JP (1) | JP2021535213A (https=) |
| KR (1) | KR20210049135A (https=) |
| CN (1) | CN112739698A (https=) |
| AU (1) | AU2019323714A1 (https=) |
| BR (1) | BR112021003529A2 (https=) |
| CA (1) | CA3110402A1 (https=) |
| IL (1) | IL281023A (https=) |
| MX (1) | MX2021002215A (https=) |
| PH (1) | PH12021550382A1 (https=) |
| SG (1) | SG11202101441SA (https=) |
| WO (1) | WO2020039093A1 (https=) |
| ZA (1) | ZA202100931B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
| EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
| US20230279000A1 (en) | 2020-02-26 | 2023-09-07 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| WO2021210970A1 (en) * | 2020-04-17 | 2021-10-21 | Dong-A St Co., Ltd. | Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators |
| WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ZA200601859B (en) | 2003-08-05 | 2008-03-26 | Vertex Pharma | Condensed pyrimidine compounds as inhibitors of voltagegated ion channels |
| WO2006044762A2 (en) * | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor |
| MY159230A (en) | 2008-10-02 | 2016-12-30 | Respivert Ltd | P38 map kinase inhibitors |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| US8691827B2 (en) | 2009-08-17 | 2014-04-08 | Merck Sharp & Dohme Corp. | Amino tetrahydro-pyridopyrimidine PDE10 inhibitors |
| BR112013002079B1 (pt) | 2010-07-27 | 2021-09-14 | Trustees Of Boston University | Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer |
| WO2016154110A1 (en) * | 2015-03-20 | 2016-09-29 | Cleave Biosciences, Inc. | Companion diagnostic for p97 inhibitor therapy and methods of use thereof |
| CA3025227A1 (en) | 2016-05-25 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
| US20230279000A1 (en) | 2020-02-26 | 2023-09-07 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
-
2019
- 2019-08-23 CN CN201980060477.XA patent/CN112739698A/zh active Pending
- 2019-08-23 CA CA3110402A patent/CA3110402A1/en active Pending
- 2019-08-23 EP EP19769387.2A patent/EP3841102B1/en active Active
- 2019-08-23 WO PCT/EP2019/072641 patent/WO2020039093A1/en not_active Ceased
- 2019-08-23 JP JP2021534826A patent/JP2021535213A/ja active Pending
- 2019-08-23 AU AU2019323714A patent/AU2019323714A1/en not_active Abandoned
- 2019-08-23 MX MX2021002215A patent/MX2021002215A/es unknown
- 2019-08-23 SG SG11202101441SA patent/SG11202101441SA/en unknown
- 2019-08-23 US US17/270,626 patent/US12221439B2/en active Active
- 2019-08-23 BR BR112021003529-0A patent/BR112021003529A2/pt not_active Application Discontinuation
- 2019-08-23 KR KR1020217008532A patent/KR20210049135A/ko not_active Ceased
-
2021
- 2021-02-10 ZA ZA2021/00931A patent/ZA202100931B/en unknown
- 2021-02-22 IL IL281023A patent/IL281023A/en unknown
- 2021-02-24 PH PH12021550382A patent/PH12021550382A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3110402A1 (en) | 2020-02-27 |
| WO2020039093A1 (en) | 2020-02-27 |
| EP3841102A1 (en) | 2021-06-30 |
| JP2021535213A (ja) | 2021-12-16 |
| US20210332041A1 (en) | 2021-10-28 |
| IL281023A (en) | 2021-04-29 |
| ZA202100931B (en) | 2021-10-27 |
| EP3841102B1 (en) | 2022-09-14 |
| CN112739698A (zh) | 2021-04-30 |
| KR20210049135A (ko) | 2021-05-04 |
| BR112021003529A2 (pt) | 2021-05-18 |
| AU2019323714A1 (en) | 2021-03-25 |
| US12221439B2 (en) | 2025-02-11 |
| PH12021550382A1 (en) | 2021-12-13 |
| SG11202101441SA (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| CO2019011543A2 (es) | Inhibidores de pd-1/pd-l1 | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CL2019001495A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih. | |
| CL2017001213A1 (es) | Bencilpropargiléter como inhibidores de la nitrificación | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CO2018011819A2 (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| MX2021009142A (es) | Inhibidores topicos de fosfoinositol 3-cinasas. | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| MX2018004977A (es) | Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer. |